Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1086MR)

This product GTTS-WQ1086MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1086MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11636MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ6121MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ7574MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ6267MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ1540MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ11183MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ5247MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ13152MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04383119
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW